Poulin R, Baker D, Poirier D, Labrie F
Medical Research Council Group in Molecular Endocrinology, CHUL Research Center, Quebec, Canada.
Breast Cancer Res Treat. 1991 Jan-Feb;17(3):197-210. doi: 10.1007/BF01806369.
This study was designed to assess the multiple steroid receptor mediated activities of a series of synthetic 'progestins' on breast cancer cell growth, using the human ZR-75-1 cell line which possesses functional estrogen (ER), androgen (AR), and glucocorticoid (GR) receptors as well as progesterone (PgR) receptors. Four 17-hydroxyprogesterone derivatives (chlormadinone acetate, CMA; cyproterone acetate, CPA; medroxyprogesterone acetate, MPA; and megestrol acetate, MGA) and two 19-nortestosterone derivatives (norethindrone, NRE, and norgestrel, NRG) were thus investigated. Based on the requirement of estrogens for PgR-mediated antiproliferative effects and the reversal of PgR-mediated action by insulin, it was found that although all 'progestins' could inhibit ZR-75-1 cell growth through the PgR at low concentrations, the relative contribution of this receptor in cell growth control is highly variable between compounds. The quantitative importance of PgR-mediated inhibition of cell proliferation was inversely related to the amplitude of the androgenic effects induced by the compounds, the AR-mediated effects increasing in the order CPA less than MGA less than CMA less than NRE less than NRG less than MPA. The specificity of these androgenic effects is further supported by their reversal upon addition of the antiandrogen hydroxyflutamide. In addition, the 17-hydroxyprogesterone derivatives, but not the 19-nortestosterone derivatives, had glucocorticoid activities at high (micromolar) concentrations, as shown by reversal of growth inhibition by the antagonist RU486 in the presence of saturating concentrations of 5 alpha-dihydro-testosterone. All 'progestins' tested, except MPA and NRE, also had some antiglucocorticoid activity, NRG being the most potent in this respect. Finally, NRE and NRG exerted a marked mitogenic effect in estrogen-free medium which was clearly mediated through the ER as shown by the competitive reversal of their action by the steroidal antiestrogen EM-139. The present results show that growth measurements of the human breast cancer cells ZR-75-1 permit, with the appropriate steroid additions, the assay of progestin, androgen, estrogen, and glucocorticoid agonistic as well as antagonistic activities of test compounds. The present study shows, somewhat surprisingly, that while the AR is almost completely responsible for the action of MPA at low concentrations, the majority of the action of NRE, NRG, and MGA is also exerted through AR, while the androgenic action of CPA plays a lower role in the growth inhibition induced by this compound.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究旨在利用人ZR - 75 - 1细胞系评估一系列合成“孕激素”对乳腺癌细胞生长的多种类固醇受体介导的活性,该细胞系具有功能性雌激素(ER)、雄激素(AR)、糖皮质激素(GR)受体以及孕激素(PgR)受体。因此,研究了四种17 - 羟孕酮衍生物(醋酸氯地孕酮,CMA;醋酸环丙孕酮,CPA;醋酸甲羟孕酮,MPA;以及醋酸甲地孕酮,MGA)和两种19 - 去甲睾酮衍生物(炔诺酮,NRE,和炔诺孕酮,NRG)。基于雌激素对PgR介导的抗增殖作用的需求以及胰岛素对PgR介导作用的逆转,发现尽管所有“孕激素”在低浓度时都可通过PgR抑制ZR - 75 - 1细胞生长,但该受体在细胞生长控制中的相对作用在不同化合物之间差异很大。PgR介导的细胞增殖抑制的定量重要性与化合物诱导的雄激素效应幅度呈负相关,AR介导的效应按以下顺序增加:CPA小于MGA小于CMA小于NRE小于NRG小于MPA。这些雄激素效应的特异性通过添加抗雄激素药物氟他胺后其作用的逆转得到进一步支持。此外,17 - 羟孕酮衍生物在高(微摩尔)浓度时有糖皮质激素活性,而19 - 去甲睾酮衍生物则没有,如在饱和浓度的5α - 二氢睾酮存在下,拮抗剂RU486可逆转生长抑制所示。除MPA和NRE外,所有测试的“孕激素”也都有一些抗糖皮质激素活性,NRG在这方面最为显著。最后,NRE和NRG在无雌激素培养基中发挥显著的促有丝分裂作用,这明显是通过ER介导的,如甾体抗雌激素EM - 139竞争性逆转其作用所示。目前的结果表明,对人乳腺癌细胞ZR - 75 - 1进行生长测量,并适当添加类固醇,可检测测试化合物的孕激素、雄激素、雌激素和糖皮质激素激动以及拮抗活性。本研究有些令人惊讶地表明,虽然AR几乎完全负责MPA在低浓度时的作用,但NRE、NRG和MGA的大部分作用也是通过AR发挥的,而CPA的雄激素作用在该化合物诱导的生长抑制中作用较小。(摘要截短至400字)